- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Proteomics
Volume 2011 (2011), Article ID 365350, 5 pages
Proteomics in Pancreatic Cancer Research
Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China
Received 1 March 2011; Revised 13 April 2011; Accepted 29 June 2011
Academic Editor: Mandi Murph
Copyright © 2011 Ruihui Geng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. Hidalgo, “Pancreatic cancer,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1605–1617, 2010.
- V. C. Wasinger, S. J. Cordwell, A. Cerpa-Poljak et al., “Progress with gene-product mapping of the mollicutes: mycoplasma genitalium,” Electrophoresis, vol. 16, no. 7, pp. 1090–1094, 1995.
- R. L. Moritz, A. R. Skandarajah, H. Ji, et al., “Proteomic analysis of colorectal cancer: prefractionation strategies using two-dimensional free-flow electrophoresis,” Comparative and Functional Genomics, vol. 6, no. 4, pp. 236–243, 2005.
- T. Rabilloud, “Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains,” Proteomics, vol. 2, no. 1, pp. 3–10, 2002.
- Y. Rong, D. Jin, C. Hou et al., “Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2,” BMC Gastroenterology, vol. 10, article 68, 2010.
- J. Minden, “Comparative proteomics and difference gel electrophoresis,” BioTechniques, vol. 43, no. 6, pp. 739–745, 2007.
- G. M. Liumbruno, “Proteomics: applications in transfusion medicine,” Blood Transfusion, vol. 6, no. 2, pp. 70–85, 2008.
- M. J. Page, T. A. Griffiths, M. R. Bleackley, et al., “Proteomics: applications relevant to transfusion medicine,” Transfusion Medicine Reviews, vol. 20, no. 1, pp. 63–74, 2006.
- B. F. Cravatt, G. M. Simon, and J. R. Yates III, “The biological impact of mass-spectrometry-based proteomics,” Nature, vol. 450, no. 7172, pp. 991–1000, 2007.
- D. H. Conrad, J. Goyette, and P. S. Thomas, “Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening,” Journal of General Internal Medicine, vol. 23, supplement 1, pp. 78–84, 2008.
- A. Motoyama and J. R. Yates III, “Multidimensional LC separations in shotgun proteomics,” Analytical Chemistry, vol. 80, no. 19, pp. 7187–7193, 2008.
- B. Domon and R. Aebersold, “Mass spectrometry and protein analysis,” Science, vol. 312, no. 5771, pp. 212–217, 2006.
- M. R. Roe and T. J. Griffin, “Gel-free mass spectrometry-based high throughput proteomics: tools for studying biological response of proteins and proteomes,” Proteomics, vol. 6, no. 17, pp. 4678–4687, 2006.
- S. Tonack, M. Aspinall-O'Dea, R. E. Jenkins et al., “A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ,” Journal of Proteomics, vol. 73, no. 2, pp. 352–356, 2009.
- Y. Zhao, W. N. Lee, S. Lim et al., “Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells,” Analytical Chemistry, vol. 81, no. 2, pp. 764–771, 2009.
- D. A. Hall, J. Ptacek, and M. Snyder, “Protein microarray technology,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 161–167, 2007.
- Q. Xu and K. S. Lam, “Protein and chemical microarrays-powerful tools for proteomics,” Journal of Biomedicine and Biotechnology, vol. 2003, no. 5, pp. 257–266, 2003.
- C. Schröder, A. Jacob, S. Tonack et al., “Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies,” Molecular and Cellular Proteomics, vol. 9, no. 6, pp. 1271–1280, 2010.
- Y. P. Lim, “Mining the tumor phosphoproteome for cancer markers,” Clinical Cancer Research, vol. 11, no. 9, pp. 3163–3169, 2005.
- T. Nagashima, M. Oyama, H. Kozuka-Hata, et al., “Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells,” Cancer Genomics and Proteomics, vol. 5, no. 3-4, pp. 161–168, 2008.
- S. A. Johnson and T. Hunter, “Phosphoproteomics finds its timing,” Nature Biotechnology, vol. 22, no. 9, pp. 1093–1094, 2004.
- H. Ijichi, M. Otsuka, K. Tateishi et al., “Smad4-independent regulation of p21/WAF1 by transforming growth factor-β,” Oncogene, vol. 23, no. 5, pp. 1043–1051, 2004.
- A. Jazag, H. Ijichi, F. Kanai et al., “Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-β,” Oncogene, vol. 24, no. 4, pp. 662–671, 2005.
- K. Mikuriya, Y. Kuramitsu, S. Ryozawa et al., “Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry,” International Journal of Oncology, vol. 30, no. 4, pp. 849–855, 2007.
- L. Dai, C. Li, K. A. Shedden et al., “Quantitative proteomic profiling studies of pancreatic cancer stem cells,” Journal of Proteome Research, vol. 9, no. 7, pp. 3394–3402, 2010.
- L. D. Roy, M. Sahraei, D. B. Subramani et al., “MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition,” Oncogene, vol. 30, no. 12, pp. 1449–1459, 2011.
- D. Basso, E. Greco, P. Fogar et al., “Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications,” Clinica Chimica Acta, vol. 357, no. 2, pp. 184–189, 2005.
- F. Navaglia, P. Fogar, D. Basso et al., “Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 6, pp. 713–723, 2009.
- J. Koopmann, P. Buckhaults, D. A. Brown et al., “Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers,” Clinical Cancer Research, vol. 10, no. 7, pp. 2386–2392, 2004.
- J. Matsubara, K. Honda, M. Ono et al., “Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 1, pp. 160–171, 2011.
- T. H. Patwa, C. Li, L. M. Poisson et al., “The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray,” Electrophoresis, vol. 30, no. 12, pp. 2215–2226, 2009.
- Z. L. Sun, Y. Zhu, F. Q. Wang et al., “Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers,” Biochimica et Biophysica Acta, vol. 1774, no. 6, pp. 764–771, 2007.
- G. M. Fiedler, A. B. Leichtle, J. Kase et al., “Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 11, pp. 3812–3819, 2009.
- G. A. Scheele, “Two dimensional gel analysis of soluble proteins. Characterization of guinea pig exocrine pancreatic proteins,” Journal of Biological Chemistry, vol. 250, no. 14, pp. 5375–5385, 1975.
- M. Tian, Y. Z. Cui, G. H. Song et al., “Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients,” BMC Cancer, vol. 8, article 241, 2008.
- K. Kojima, S. Asmellash, C. A. Klug, et al., “Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer,” Journal of Gastrointestinal Surgery, vol. 12, no. 10, pp. 1683–1690, 2008.
- D. Cecconi, M. Donadelli, A. Scarpa et al., “Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A,” Journal of Proteome Research, vol. 4, no. 6, pp. 1909–1916, 2005.
- S. Mori-Iwamoto, Y. Kuramitsu, S. Ryozawa et al., “Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine,” International Journal of Oncology, vol. 31, no. 6, pp. 1345–1350, 2007.
- K. Taba, Y. Kuramitsu, S. Ryozawa et al., “KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine,” Chemotherapy, vol. 57, no. 1, pp. 12–16, 2011.
- Y. Kuramitsu, K. Taba, S. Ryozawa et al., “Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry,” Anticancer Research, vol. 30, no. 9, pp. 3367–3372, 2010.
- K. Taniuchi, H. Nakagawa, T. Nakamura et al., “Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell,” Cancer Research, vol. 65, no. 1, pp. 105–112, 2005.
- T. Hibi, T. Mori, M. Fukuma et al., “Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 8, pp. 2864–2871, 2009.
- J. M. Löhr, R. Faissner, P. Findeisen, et al., “Proteome analysis-basis for individualized pancreatic carcinoma therapy?” Internist, vol. 47, supplement 1, pp. S40–S48, 2006.
- D. J. Shields, S. Niessen, E. A. Murphy et al., “RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 5, pp. 2189–2194, 2010.
- L. C. Fry, K. Mönkemüller, and P. Malfertheiner, “Molecular markers of pancreatic cancer: development and clinical relevance,” Langenbeck's Archives of Surgery, vol. 393, no. 6, pp. 883–890, 2008.